Novel insights into metabolic‐associated steatotic liver disease preclinical models
Metabolic‐associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and...
Gespeichert in:
| Veröffentlicht in: | Liver international 2024-03, Vol.44 (3), p.644-662 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 662 |
|---|---|
| container_issue | 3 |
| container_start_page | 644 |
| container_title | Liver international |
| container_volume | 44 |
| creator | Montero‐Vallejo, Rocío Maya‐Miles, Douglas Ampuero, Javier Martín, Franz Romero‐Gómez, Manuel Gallego‐Durán, Rocío |
| description | Metabolic‐associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims. |
| doi_str_mv | 10.1111/liv.15830 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2920572203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2920572203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3880-1fecad38cdc1fe1e608cfc065dacab5793c738322327f3bfed9de6d128ce61343</originalsourceid><addsrcrecordid>eNp1kLtOwzAUhi0EoqUw8AIoEgsMob40iTOiikulChbKGjn2Cbhy4hK7Rd14BJ6RJ8ElpQMSXs4_fPqOz4_QKcFXJLyh0asrknCG91CfjDIeM8rI_i5T1kNHzs0xJnmekEPUY5zmhCdJH80e7ApMpBunX169C8HbqAYvSmu0_Pr4FM5ZqYUHFTkPwluvZRQWQhsp7UA4iBYtSKMbLYWJaqvAuGN0UAnj4GQ7B2h2e_M0vo-nj3eT8fU0loxzHJMKpFCMSyVDJJBiLiuJ00QJKcoky5nMGN8cQLOKlRWoXEGqCOUSUsJGbIAuOu-itW9LcL6otZNgjGjALl1Bc4qTjFLMAnr-B53bZduE3wUq-DHHIxKoy46SrXWuhapYtLoW7boguNh0XYTTi5-uA3u2NS7LGtSO_C03AMMOeNcG1v-biunkuVN-A5xNiqU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2932708041</pqid></control><display><type>article</type><title>Novel insights into metabolic‐associated steatotic liver disease preclinical models</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Montero‐Vallejo, Rocío ; Maya‐Miles, Douglas ; Ampuero, Javier ; Martín, Franz ; Romero‐Gómez, Manuel ; Gallego‐Durán, Rocío</creator><creatorcontrib>Montero‐Vallejo, Rocío ; Maya‐Miles, Douglas ; Ampuero, Javier ; Martín, Franz ; Romero‐Gómez, Manuel ; Gallego‐Durán, Rocío</creatorcontrib><description>Metabolic‐associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.15830</identifier><identifier>PMID: 38291855</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>animal models ; Cirrhosis ; Fatty liver ; Genetic factors ; Hepatocellular carcinoma ; Liver ; Liver diseases ; liver fibrosis ; MASLD ; steatohepatitis ; Steatosis</subject><ispartof>Liver international, 2024-03, Vol.44 (3), p.644-662</ispartof><rights>2024 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2024 The Authors. Liver International published by John Wiley & Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3880-1fecad38cdc1fe1e608cfc065dacab5793c738322327f3bfed9de6d128ce61343</citedby><cites>FETCH-LOGICAL-c3880-1fecad38cdc1fe1e608cfc065dacab5793c738322327f3bfed9de6d128ce61343</cites><orcidid>0000-0002-9452-1661 ; 0000-0001-8510-9512 ; 0000-0001-8494-8947</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.15830$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.15830$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38291855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Montero‐Vallejo, Rocío</creatorcontrib><creatorcontrib>Maya‐Miles, Douglas</creatorcontrib><creatorcontrib>Ampuero, Javier</creatorcontrib><creatorcontrib>Martín, Franz</creatorcontrib><creatorcontrib>Romero‐Gómez, Manuel</creatorcontrib><creatorcontrib>Gallego‐Durán, Rocío</creatorcontrib><title>Novel insights into metabolic‐associated steatotic liver disease preclinical models</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Metabolic‐associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims.</description><subject>animal models</subject><subject>Cirrhosis</subject><subject>Fatty liver</subject><subject>Genetic factors</subject><subject>Hepatocellular carcinoma</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>liver fibrosis</subject><subject>MASLD</subject><subject>steatohepatitis</subject><subject>Steatosis</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kLtOwzAUhi0EoqUw8AIoEgsMob40iTOiikulChbKGjn2Cbhy4hK7Rd14BJ6RJ8ElpQMSXs4_fPqOz4_QKcFXJLyh0asrknCG91CfjDIeM8rI_i5T1kNHzs0xJnmekEPUY5zmhCdJH80e7ApMpBunX169C8HbqAYvSmu0_Pr4FM5ZqYUHFTkPwluvZRQWQhsp7UA4iBYtSKMbLYWJaqvAuGN0UAnj4GQ7B2h2e_M0vo-nj3eT8fU0loxzHJMKpFCMSyVDJJBiLiuJ00QJKcoky5nMGN8cQLOKlRWoXEGqCOUSUsJGbIAuOu-itW9LcL6otZNgjGjALl1Bc4qTjFLMAnr-B53bZduE3wUq-DHHIxKoy46SrXWuhapYtLoW7boguNh0XYTTi5-uA3u2NS7LGtSO_C03AMMOeNcG1v-biunkuVN-A5xNiqU</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Montero‐Vallejo, Rocío</creator><creator>Maya‐Miles, Douglas</creator><creator>Ampuero, Javier</creator><creator>Martín, Franz</creator><creator>Romero‐Gómez, Manuel</creator><creator>Gallego‐Durán, Rocío</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9452-1661</orcidid><orcidid>https://orcid.org/0000-0001-8510-9512</orcidid><orcidid>https://orcid.org/0000-0001-8494-8947</orcidid></search><sort><creationdate>202403</creationdate><title>Novel insights into metabolic‐associated steatotic liver disease preclinical models</title><author>Montero‐Vallejo, Rocío ; Maya‐Miles, Douglas ; Ampuero, Javier ; Martín, Franz ; Romero‐Gómez, Manuel ; Gallego‐Durán, Rocío</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3880-1fecad38cdc1fe1e608cfc065dacab5793c738322327f3bfed9de6d128ce61343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>animal models</topic><topic>Cirrhosis</topic><topic>Fatty liver</topic><topic>Genetic factors</topic><topic>Hepatocellular carcinoma</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>liver fibrosis</topic><topic>MASLD</topic><topic>steatohepatitis</topic><topic>Steatosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Montero‐Vallejo, Rocío</creatorcontrib><creatorcontrib>Maya‐Miles, Douglas</creatorcontrib><creatorcontrib>Ampuero, Javier</creatorcontrib><creatorcontrib>Martín, Franz</creatorcontrib><creatorcontrib>Romero‐Gómez, Manuel</creatorcontrib><creatorcontrib>Gallego‐Durán, Rocío</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montero‐Vallejo, Rocío</au><au>Maya‐Miles, Douglas</au><au>Ampuero, Javier</au><au>Martín, Franz</au><au>Romero‐Gómez, Manuel</au><au>Gallego‐Durán, Rocío</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel insights into metabolic‐associated steatotic liver disease preclinical models</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2024-03</date><risdate>2024</risdate><volume>44</volume><issue>3</issue><spage>644</spage><epage>662</epage><pages>644-662</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Metabolic‐associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38291855</pmid><doi>10.1111/liv.15830</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0002-9452-1661</orcidid><orcidid>https://orcid.org/0000-0001-8510-9512</orcidid><orcidid>https://orcid.org/0000-0001-8494-8947</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2024-03, Vol.44 (3), p.644-662 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2920572203 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | animal models Cirrhosis Fatty liver Genetic factors Hepatocellular carcinoma Liver Liver diseases liver fibrosis MASLD steatohepatitis Steatosis |
| title | Novel insights into metabolic‐associated steatotic liver disease preclinical models |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A46%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20insights%20into%20metabolic%E2%80%90associated%20steatotic%20liver%20disease%20preclinical%20models&rft.jtitle=Liver%20international&rft.au=Montero%E2%80%90Vallejo,%20Roc%C3%ADo&rft.date=2024-03&rft.volume=44&rft.issue=3&rft.spage=644&rft.epage=662&rft.pages=644-662&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.15830&rft_dat=%3Cproquest_cross%3E2920572203%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2932708041&rft_id=info:pmid/38291855&rfr_iscdi=true |